SciSparc Ltd. (NASDAQ:SPRC) Short Interest Update

SciSparc Ltd. (NASDAQ:SPRC) saw a large drop in short interest in May. As of May 15th, there was short interest totaling 7,194 shares, a drop of 76.8% from the April 30th total of 31,066 shares. Based on an average daily volume of 27,949 shares, the short-interest ratio is presently 0.3 days. Currently, 1.3% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, SciSparc presently has a consensus rating of “Sell”.

SciSparc Price Performance

NASDAQ:SPRC traded down $0.74 during trading hours on Friday, hitting $9.81. 823,710 shares of the company traded hands, compared to its average volume of 1,803,440. The firm’s 50-day simple moving average is $5.10 and its 200-day simple moving average is $9.28. SciSparc has a one year low of $2.98 and a one year high of $80.10.

SciSparc (NASDAQ:SPRC) last issued its quarterly earnings data on Wednesday, April 29th. The company reported ($31.60) earnings per share for the quarter. The business had revenue of $0.20 million during the quarter.

SciSparc News Roundup

Here are the key news stories impacting SciSparc this week:

• Positive Sentiment: NeuroThera Labs received conditional regulatory approval from the TSX Venture Exchange for its acquisition of a majority stake in CliniQuantum, a development that may increase the likelihood the transaction closes. SciSparc Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
• Neutral Sentiment: SPRC was halted several times intraday under LULD rules, reflecting unusually high volatility and strong trading interest rather than a direct change in fundamentals.
• Neutral Sentiment: Coverage from market outlets highlighted the move as a sharp speculative rally tied to the regulatory milestone, reinforcing that sentiment rather than financial results is driving the stock.
• Negative Sentiment: Recent short-interest and hedge fund data suggest limited institutional support, which may make the shares more vulnerable to abrupt reversals after the spike.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.